Food Effect Study of Abiraterone Acetate for Treatment of Patients With Castration-Resistant Prostate Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by University of Chicago
National Cancer Institute (NCI)
Information provided by (Responsible Party):
University of Chicago Identifier:
First received: February 15, 2012
Last updated: September 10, 2015
Last verified: September 2015
This randomized phase II trial studies the best way to give abiraterone acetate in treating patients with castration-resistant prostate cancer. Abiraterone acetate is effective in treating castrate resistant prostate cancer and is taken in the fasting state. However, the body's absorption of abiraterone is increased with food intake. This study will test the whether a lower dose of abiraterone taken with food has a similar effect on prostate specific antigen (PSA) compared to full dose taken fasting.

Condition Intervention Phase
Castration-resistant Prostate Cancer
Stage IV Prostate Cancer
Drug: abiraterone acetate
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Randomized Pilot Study Evaluating the Food Effect on the Pharmacokinetics and Pharmacodynamics of Abiraterone Acetate in Men With Castrate Resistant Prostate Cancer

Resource links provided by NLM:

Further study details as provided by University of Chicago:

Primary Outcome Measures:
  • Change in PSA level [ Time Frame: From baseline to 12 weeks ] [ Designated as safety issue: No ]
    Analyzed on a log scale.

Secondary Outcome Measures:
  • Progression-free survival (PFS) [ Time Frame: Defined as the duration of time from start of treatment to time of progression (by either PSA or RECIST) or death, whichever occurs first, assessed up to 1 year ] [ Designated as safety issue: No ]
  • Peak Plasma Concentration (Cmax) of abiraterone acetate, obtained from steady states PK samples [ Time Frame: Day 8 ] [ Designated as safety issue: No ]
  • Peak Plasma Concentration (Cmax) of abiraterone acetate, obtained from steady states PK samples [ Time Frame: At 2 months (2 hours post-dose) ] [ Designated as safety issue: No ]
  • Peak Plasma Concentration (Cmax) of abiraterone acetate, obtained from steady states PK samples [ Time Frame: At 3 months (2 hours post-dose) ] [ Designated as safety issue: No ]
  • Peak Plasma Concentration (Cmax) of abiraterone acetate, obtained from steady states PK samples [ Time Frame: At 4 months (2 hours post-dose) ] [ Designated as safety issue: No ]
  • The effects of dosing arm percentage change on adrenal androgen production (DHEA, DHEA-S) [ Time Frame: From baseline to every 3 months ] [ Designated as safety issue: No ]
  • Incidence of adverse events (AEs) [ Time Frame: Assessed up to 1 year ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 72
Study Start Date: January 2012
Estimated Study Completion Date: January 2017
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Arm I (fasting)
Patients receive abiraterone acetate PO daily first thing in morning after an overnight fast of at least 8 hours.
Drug: abiraterone acetate
Given PO
Other Names:
  • CB7630
  • Zytiga
Experimental: Arm II (fed)
Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.
Drug: abiraterone acetate
Given PO
Other Names:
  • CB7630
  • Zytiga

Detailed Description:


I. To compare the pharmacodynamic effect of reduced dose (250mg daily) abiraterone acetate in the prandial state (250mg-Fed) to the full, standard 1000mg daily dose in the fasting state (1000mg-Fasting) as assessed by change in serum prostate-specific antigen (PSA).


I. To evaluate the effect of prandial states on plasma levels and the intra-patient pharmacokinetic variability of abiraterone acetate.

II. To evaluate the safety profile of reduced dose abiraterone acetate taken in the prandial state.

III. To evaluate the pharmacodynamic effect of reduced dose abiraterone acetate in the prandial state as assessed by reduction in the extra-gonadal androgen dihydroepiadrosterone sulfate (DHEA-S) and dihydroepiandrostenedione (DHEA).

IV. To evaluate the effect of prandial state on time to disease progression (Working group criteria).

OUTLINE: Patients are randomized to one of two treatment arms.

ARM I: Patients receive abiraterone acetate orally (PO) daily first thing in morning after an overnight fast of at least 8 hours.

ARM II: Patients receive abiraterone acetate PO daily within 30 minutes of a conventional low-fat breakfast.

In both arms, courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Both arms will also be treated with prednisone 5mg twice daily.

After completion of study treatment, patients are followed up within 30 days.


Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed prostate cancer with progressive disease defined as either:

    • 2 or more new lesions on bone scan or
    • Progressive disease on computed tomography (CT)/magnetic resonance imaging (MRI) according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 criteria or
    • Rising prostate-specific antigen (PSA): PSA evidence for progressive prostate cancer consists of a minimum PSA level of at least 2 ng/ml, which has subsequently risen on at least 2 successive occasions, at least 2 weeks apart
  • Evidence of castration resistance defined as disease progression despite a testosterone level < 50 ng/dL (or surgical castration)
  • Any prior therapy for castrate disease is acceptable except prior abiraterone, which is excluded; a minimum washout of 28 days for any other anticancer therapy prior to first dose of study drug is required

    • Any other radiotherapy or radionuclide require 28-day washout prior to first dose of study drug
    • Denosumab or zoledronic acid are allowed
  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Total bilirubin =< 1.5 x the upper limit of normal
  • Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Therapy with other hormonal therapy, including any dose of megestrol acetate (Megace), finasteride (Proscar), dutasteride (Avodart), or any herbal product known to decrease PSA levels (e.g., saw palmetto and PC-SPES), or any systemic corticosteroid (other than prednisone =< 10 mg/day) within 4 weeks prior to first dose of study drug
  • Therapy with supplements or complementary medicines/botanicals within 4 weeks of first dose of study drug is excluded with the following exceptions:

    • Conventional multivitamin supplements
    • Selenium
    • Lycopene
    • Soy supplements
  • Inability to swallow capsules or known gastrointestinal malabsorption
  • History of other malignancies, with the exception of adequately treated non-melanoma skin cancer or adequately treated superficial bladder cancer or other solid tumors curatively treated with no evidence of disease for >= 5 years from enrollment
  • Blood pressure that is not controlled despite > 2 oral agents (systolic blood pressure [SBP] > 160 and diastolic blood pressure [DBP] > 90 documented during the screening period with no subsequent blood pressure readings < 160/100)
  • Serum potassium (K)+ < 3.5 mmoL/L on more than one reading within the screening period
  • Serious intercurrent infections or non-malignant medical illnesses that are uncontrolled
  • Active psychiatric illness/social situations that would limit compliance with protocol requirements
  • New York Heart Association (NYHA) class II, NYHA class III, or IV congestive heart failure (any symptomatic heart failure)
  • Concurrent therapy with strong inhibitors or inducers of Cytochrome P450 (CYP)3A4 due to concerning possible drug-drug interactions with abiraterone
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01543776

Contact: Elia Martinez, RN 773-702-3623

United States, Georgia
Emory University Winship Cancer Institute Recruiting
Atlanta, Georgia, United States, 30322
Contact: Erika Jodice    404-778-4083   
United States, Illinois
University of Chicago Recruiting
Chicago, Illinois, United States, 60637-1470
Contact: Russell Z. Szmulewitz    773-702-7609   
Principal Investigator: Russell Z. Szmulewitz         
North Shore University Health System Recruiting
Evanston, Illinois, United States, 60201
Contact: Susan Greve    847-657-5954   
Ingalls Memorial Hospital Recruiting
Harvey, Illinois, United States, 60430
Contact: Peggy Marriott    708-915-6119   
Principal Investigator: Mark Kozloff, M.D.         
Illinois Cancer Care Recruiting
Peoria, Illinois, United States, 61615
Contact: Jamie Harper, BS    309-243-3618   
Principal Investigator: Sachdev P Thomas, MD         
National University Hospital Recruiting
Singapore, Singapore
Contact: Ivy Toy Ann Lin   
Sponsors and Collaborators
University of Chicago
National Cancer Institute (NCI)
Principal Investigator: Russell Szmulewitz University of Chicago
  More Information

No publications provided

Responsible Party: University of Chicago Identifier: NCT01543776     History of Changes
Other Study ID Numbers: 11-0709  NCI-2012-00116 
Study First Received: February 15, 2012
Last Updated: September 10, 2015
Health Authority: United States: Institutional Review Board
United States: Federal Government

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms processed this record on February 11, 2016